Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | RHEB | Q15382 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | OGG1 | O15527 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28642433 | 0.82 | CYP1A2 (0.37) | WDR5LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL10102796 | 0.82 | WDR5 (0.50) | WDR5LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL21409 | 0.78 | MAOB (0.61) | MAOBRXRARXRBRXRG | |
| SCHEMBL29924283 | 0.77 | RHEB (0.52) | WDR5LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL6206121 | 0.77 | RHEB (0.52) | WDR5LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL1855228 | 0.75 | — | — | |
| SCHEMBL16890555 | 0.75 | RHEB (0.50) | WDR5LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL177674 | 0.74 | TSHR (0.47) | ALDH1A1TSHRCYP2C19 | |
| SCHEMBL10715309 | 0.73 | MAPT (0.54) | WDR5SMN1; SMN2ALDH1A1TSHRSLC6A4 | |
| SCHEMBL535619 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119978389-A | Boron-containing oligomer for aging-resistant high-transparency addition-type silicon rubber, and preparation method and application thereof | 中国科学院化学研究所 | 2025-05-13 | — | — | CN | claimed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | claimed |
| US-11426393-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2022-08-30 | — | — | US | claimed |
| WO-2022159439-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| CN-110483291-B | Synthesis method of (E) -beta-aryl-beta, gamma-unsaturated ester compound | 安阳师范学院 | 2021-09-10 | — | — | CN | claimed |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2021-05-13 | — | — | US | claimed |
| US-9233967-B2 | Process for the preparation of sitagliptin and intermediate compounds | CIPLA LIMITED (IN) | 2016-01-12 | — | — | US | claimed |
| US-20150197523-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND INTERMEDIATE COMPOUNDS | CIPLA LIMITED (IN) | 2015-07-16 | — | — | US | claimed |
| EP-2882752-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND INTERMEDIATE COMPOUNDS | Cipla Limited (IN) | 2015-06-17 | — | — | EP | claimed |
| US-8921299-B2 | Detergents having acceptable color | THE PROCTER & GAMBLE COMPANY (US) | 2014-12-30 | — | — | US | claimed |
| WO-2014023930-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND INTERMEDIATE COMPOUNDS | CIPLA LIMITED (IN) | 2014-02-13 | — | — | WO | claimed |
| US-7919618-B2 | Preparing (3'-chloro-biphenyl-4-yl)-(1-pyrimidin-2-yl-piperidin-4-yl)-methanone, or a salt or solvate thereof by contacting (3'-chloro-biphenyl-4-yl)-piperidine-4-yl-methanone with 2-chloropyrimidine in base; cataysis using bis(triphenylphosphine)palladium(II) dichloride; nervous system disorders | LEXICON PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | claimed |
| EP-2084144-B1 | SYNTHESIS OF PIPERAZINES, PIPERIDINES AND RELATED COMPOUNDS | LEXICON PHARMACEUTICALS INC (US) | 2011-02-23 | — | — | EP | claimed |
| EP-2084144-A2 | SYNTHESIS OF PIPERAZINES, PIPERIDINES AND RELATED COMPOUNDS | Lexicon Pharmaceuticals, Inc. (US) | 2009-08-05 | — | — | EP | claimed |
| US-20080177070-A1 | Synthesis of piperazines, piperidines and related compounds | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-07-24 | — | — | US | claimed |
| WO-2008019279-A2 | SYNTHESIS OF PIPERAZINES, PIPERIDINES AND RELATED COMPOUNDS | LEXICON PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | claimed |
| US-12641999-B2 | Composition for organic optoelectronic device, organic optoelectronic device and display device | SAMSUNG SDI CO., LTD. (KR) | 2026-05-26 | — | — | US | disclosed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-5455252-A | Antiinflammatory agent, immunosuppressant, antiallergen, skin disorders, bronchodilator, analgesic | SYNTEX (U.S.A.) INC. (US) | 1995-10-03 | — | — | US | disclosed |
| WO-1994022852-A1 | QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11426393-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | WDR5 4262/4885LMNA 2347/4885MAPK1 2780/4885 |
| US-12641999-B2 | Composition for organic optoelectronic device, organic optoelectronic device and display device | NR2E3, OXER1, NR0B2 | WDR5 2629/4885LMNA 2771/4885MAPK1 846/4885 |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | WDR5 4262/4885LMNA 2347/4885MAPK1 2780/4885 |
| US-20080177070-A1 | Synthesis of piperazines, piperidines and related compounds | CTPS2, PLP2, DHPS | WDR5 512/4885LMNA 3221/4885MAPK1 2844/4885 |
| US-20150197523-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND INTERMEDIATE COMPOUNDS | DPP4, DPP7, DPP9 | WDR5 2942/4885LMNA 2767/4885MAPK1 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.